The Coalition Calls on Congress to Intervene as Courts Undermine the ‘Skinny Label’ Framework, Preventing Generic Competition While Drug Companies Profit WASHINGTON, DC: Recently, the U.S. Court of Appeals for the Federal Circuit upheld the verdict in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., subjecting Teva to a $234 million judgment that includes damages for the period […]

Continue Reading

New Report Highlights How AbbVie’s Patent System Gaming Keeps Prices High for U.S. Patients WASHINGTON D.C. – In case you missed it, Axios reported this week that international sales of Humira, a medicine that treats a number of chronic conditions and is widely prescribed and used by millions of people around the world, are declining due to the […]

Continue Reading

Congress Must Stop Major Drug Companies from Abusing the U.S. Patent System to Delay or Prevent Patients from Accessing More Affordable Generic Alternative Medications and Treatments. WASHINGTON D.C. – In case you missed it, the Senate Judiciary Committee voted unanimously to pass a package of four bills relating to drug pricing, including S. 1435, the Affordable Prescriptions for […]

Continue Reading

Join the Discussion to Learn More About How the U.S Public is a Vital Stakeholder in the U.S. Patent System. WASHINGTON D.C. – As part of Patent Quality Week, the Public Interest Patent Law Institute and the Coalition Against Patent Abuse (CAPA) are hosting a conversation highlighting how patent law does – or at least should – […]

Continue Reading

Join the Discussion to Learn More About How the U.S Public is a Vital Stakeholder in the U.S. Patent System. WASHINGTON D.C. – As part of Patent Quality Week, the Public Interest Patent Law Institute and the Coalition Against Patent Abuse (CAPA) are hosting a conversation highlighting how patent law does – or at least should – […]

Continue Reading

Part VI: IPR & Anemia – An Effective, Low-Cost Tool for Resolving Patent Disputes Since the inter partes review (IPR) process was established under the America Invents Act in 2011, IPR has become a popular and cost-effective tool compared to traditional patent litigation.  Even the U.S. Supreme Court has described the IPR process as a way to […]

Continue Reading

Lawmakers Must Continue to Work with Industry Leaders, Experts to Prevent Manipulations of the U.S. Patent System WASHINGTON D.C. – Today, the Senate Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer Rights held a hearing entitled, “A Prescription for Change: Cracking Down on Anticompetitive Conduct in Prescription Drug Markets” to examine anticompetitive tactics used by many […]

Continue Reading

WASHINGTON, DC – In case you missed it, the Coalition Against Patent Abuse’s Executive Director Matthew Lane penned an op-ed in Morning Consult today on the need to address patent abuse and anti-competitive pricing tactics used by some major pharmaceutical companies.  The U.S. drug system is based on a balance between rewarding innovations with temporary market exclusivity and […]

Continue Reading

WASHINGTON, DC – In the wake of today’s U.S. Supreme Court decision in the United States v. Arthrex Inc. case, the Coalition Against Patent Abuse (CAPA) said that it’s critical for Congress to now address this decision and work to protect and strengthen the Inter Partes Review (IPR) within the U.S. Patent & Trademark Office (USPTO), by ensuring […]

Continue Reading

WASHINGTON D.C. – Matrix Global Advisors (MGA) released a white paper that highlights how patent thickets increase barriers for American patients to access affordable biosimilar medications and treatments.  The paper explains how some biologic manufacturers prevent competition by creating patent walls with “overlapping, weaker” patents to significantly extend their drug’s monopoly and increase profits while limiting access to […]

Continue Reading